GCP
DMAC icon

GSA Capital Partners’s DiaMedica Therapeutics DMAC Stock Holding History

GSA Capital Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
58,522
+44,658
+322% +$354K 0.02% 1068
2025
Q4 		$110K Buy
+13,864
New +$104K 0.01% 1517

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GSA Capital Partners's DMAC Position: Q1 2026 in Review

GSA Capital Partners increased its DiaMedica Therapeutics (DMAC) stake by 322% in Q1 2026, buying an estimated $354K and bringing the position to 58,522 shares worth $396K. The position accounts for 0.02% of the portfolio, ranked #1068.

GSA Capital Partners first reported a position in DMAC in Q4 2025 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • GSA Capital Partners held 58,522 shares of DiaMedica Therapeutics worth $396K as of Q1 2026.
  • GSA Capital Partners bought 44,658 DiaMedica Therapeutics shares in Q1 2026, an estimated $354K.
  • DiaMedica Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1068 holding.
  • GSA Capital Partners first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.